Komori
Kidswell Bio (4584) · RiskFirst stated

S-Quatre’s Negative Net Worth and the Parent Company’s Funding Burden

First written in FY2026. . Latest entry: FY2026.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Risk of negative net worth and financial deterioration at consolidated subsidiariesA theme 42 companies write about · 43 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2018: 6 of 10 companies on the "Worse" side.

6 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 42 companies compared. The sentences above are computed from all 42.
Full recordFilings, disclosures and news, newest first
  1. FY2026First statedAnnual report

    「S-Quatre Co., Ltd. has negative net worth, with its excess of liabilities over assets amounting to ¥1,270.523 million as of 31 March 2026.」

    For S-Quatre, which is responsible for the cell therapy business, the company has disclosed for the first time the amount of its negative net worth as of 31 March 2026. The reporting company's financial statements also include ¥1,200 million in long-term loans to the affiliate.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Kidswell Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
S-Quatre’s Negative Net Worth and the Parent Company’s Funding Burden | Kidswell Bio Corporation (4584) | Komori